KPC Pharmaceuticals,Inc. (SHA:600422)

Market Cap	11.24B
Revenue (ttm)	8.08B
Net Income (ttm)	607.32M
Shares Out	756.98M
EPS (ttm)	0.81
PE Ratio	18.32
Forward PE	15.22
Dividend	0.30 (2.05%)
Ex-Dividend Date	Jul 30, 2025

Volume	19,109,500
Average Volume	14,944,463
Open	14.60
Previous Close	14.64
Day's Range	14.54 - 14.95
52-Week Range	11.92 - 18.64
Beta	0.04
RSI	54.56
Earnings Date	Aug 16, 2025

About SpringWorks Therapeutics

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotic, immunosuppressive, and others. The company provides medicine and food, skin care, oral care, private care, and time-honored food series; and other products, such as oral medication ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,275
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600422

Financial Performance

In 2024, KPC Pharmaceuticals,Inc.'s revenue was 8.40 billion, a decrease of -0.34% compared to the previous year's 8.43 billion. Earnings were 648.08 million, an increase of 19.86%.